Evaluation of Cognitive Behavioral Therapy for Long-term Pain in Rheumatic Disease, Including Validation of AE-FS
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDiakonhjemmet Hospital
About this trial
Catastrophic thinking is a risk factor for a poor prognosis for pain in general and rheumatic disease in particular, which for many contributes to a behavioral pattern characterized by avoidance. Other people with long-term pain, on the other hand, have a pattern where they suppress thoughts and feelings of fear associated with pain, and push themselves to carry out activities. An inappropriate form of endurance can help maintain and intensify pain. The AE-FS is a short version of the Avoidance-Endurance Questionnaire with different subscales for maintaining activity despite pain. AE-FS can be of great clinical utility. The study of patients with rheumatic disease and long-term pain will validate a Norwegian version of the AE-FS as well as examine how the AE-FS seen in connection with other relevant questionnaires, including the Pain Catastrophizing Scale , reflects mechanisms for change in cognitive behavioral therapy for long-term pain. The effect of the intervention is evaluated with questionnaires at baseline/start of treatment, end of treatment, two months after end of treatment and after six months.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
A rheumatic disorder and a long term pain condition
Written consent
Disqualifiers
Participation in another therapy during the study periode
Trial design
Design model
Single group
Treatments tested in this trial
Cognitive behavioral Therapy
BehavioralCognitive behavioral therapy is the psychological approach in this study. It is associated with better outcomes of rehabilitation for long-term pain in general, reduced pain intensity and less use of medication and health services, sustaining factors that provide an understanding of how thoughts and feelings affect the experience of pain. An important aim is also a reduction in pain-related rumination and worry and changed metacognition that maintains inhibiting behavior and thought patterns. A workbook for pain has been developed. It contains knowledge about pain and pain management, describes measures and homework from session to session. The treatment consists of 8 sessions with 7 weekly sessions + 1 booster session 2 months after the end of treatment. .
Treatment groups
200 Participants
are divided into 1 treatment groupGroup A: Cognitive behavioral TherapyExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Validation of AE-FS
1\. The AE-FS questionnaire can be of great clinical value for mapping behavior and thoughts in mild and severe pain, both to predict long-term pain and as an educational tool in the treatment of patients. In the project, we will validate the form, by assessing its suitability for our patient group and compliance with other validated forms which, among other things, measure pain, depressive symptoms, anxiety symptoms and function.
Time frame
8 months2
Evaluation of cognitive behavioral therapy for long-term pain in rheumatic disease - Feasibility
In the project, we also to evaluate the feasibility of the treatment:Feasibility and satisfaction, including attendance, dropouts, etc.
Time frame
8 months3
Evaluation of cognitive behavioral therapy for long-term pain in rheumatic disease - Pain
Pain, measured by the Brief Pain Inventory questionnaire - short form
Time frame
8 months4
Evaluation of cognitive behavioral therapy for long-term pain in rheumatic disease - General symptoms
General symptoms, measured by the PROMIS-29 questionnaire (Patient reported outcomes measurement information system).
Time frame
8 monthsSecondary outcomes
1
Analyses of predictors and mediators
3\. We also want to investigate whether negative thought and reaction and behavior patterns in long-term pain measured by AE-FS and/or PCS can predict and/or mediate treatment response when it comes to pain.
Time frame
8 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov